Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2021- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide- Abbott’s PFO closure technology helps to prevent blood clots from passing from the right to left side of the heart from where they can travel to the brain and cause a stroke- The Talisman system offers the industry's widest range of device sizes in the U.S. and the occluder comes pre-attached to the delivery cable, making the device easier for physicians to use
-
Sep 28, 2021- People with diabetes who use the FreeStyle Libre mobile app experience clinically significant improved time in target range- Data reinforce the benefits of mobile apps, which can remotely connect people living with diabetes to healthcare professionals during COVID-19- Abbott is joining Novo Nordisk and The diaTribe Foundation in raising awareness and education on Time in Range
-
Sep 22, 2021- New enhancements to Abbott's Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures- Epic Plus designed to help patients with more complex cases of aortic or mitral regurgitation or stenosis- Latest device builds on history of surgical valve replacement as a reliable and critical therapy option for patients with valvular heart disease
- Sep 20, 2021- Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery- With Portico approval, Abbott offers the industry's most comprehensive portfolio of structural heart solutions in the U.S.
- Sep 2, 2021Acquisition builds upon Abbott's leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots
- Aug 30, 2021- New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device- Amulet device is the first and only minimally invasive option approved for LAA occlusion that does not require blood-thinning medication following implantation- Trial results supported recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation
- Aug 27, 2021- The GUIDE-HF study examined the potential impact of Abbott's CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device- Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease
- Aug 16, 2021- Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation- The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with atrial fibrillation, the most common sustained cardiac arrhythmia